Literature DB >> 12547827

Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor.

Jin-Peng Sun1, Alexander A Fedorov, Seung-Yub Lee, Xiao-Ling Guo, Kui Shen, David S Lawrence, Steven C Almo, Zhong-Yin Zhang.   

Abstract

Protein-tyrosine phosphatase 1B (PTP1B) has been implicated as an important regulator in several signaling pathways including those initiated by insulin and leptin. Potent and specific PTP1B inhibitors could serve as useful tools in elucidating the physiological functions of PTP1B and may constitute valuable therapeutics in the treatment of several human diseases. We have determined the crystal structure of PTP1B in complex with compound 2, the most potent and selective PTP1B inhibitor reported to date. The structure at 2.15-A resolution reveals that compound 2 simultaneously binds to the active site and a unique proximal noncatalytic site formed by Lys-41, Arg-47, and Asp-48. The structural data are further corroborated by results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with compound 2 and several of its variants. Although many of the residues important for interactions between PTP1B and compound 2 are not unique to PTP1B, the combinations of all contact residues differ between PTP isozymes, which provide a structural basis for potent and selective PTP1B inhibition. Our data further suggest that potent, yet highly selective, PTP1B inhibitory agents can be acquired by targeting the area defined by residues Lys-41, Arg-47, and Asp-48, in addition to the previously identified second aryl phosphate-binding pocket.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547827     DOI: 10.1074/jbc.M212491200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.

Authors:  Katherine A Rawls; Christoph Grundner; Jonathan A Ellman
Journal:  Org Biomol Chem       Date:  2010-07-19       Impact factor: 3.876

2.  Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).

Authors:  Xian Zhang; Yantao He; Sijiu Liu; Zhihong Yu; Zhong-Xing Jiang; Zhenyun Yang; Yuanshu Dong; Sarah C Nabinger; Li Wu; Andrea M Gunawan; Lina Wang; Rebecca J Chan; Zhong-Yin Zhang
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

Review 3.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 4.  Structural genomics of protein phosphatases.

Authors:  Steven C Almo; Jeffrey B Bonanno; J Michael Sauder; Spencer Emtage; Teresa P Dilorenzo; Vladimir Malashkevich; Steven R Wasserman; S Swaminathan; Subramaniam Eswaramoorthy; Rakhi Agarwal; Desigan Kumaran; Mahendra Madegowda; Sugadev Ragumani; Yury Patskovsky; Johnjeff Alvarado; Udupi A Ramagopal; Joana Faber-Barata; Mark R Chance; Andrej Sali; Andras Fiser; Zhong-yin Zhang; David S Lawrence; Stephen K Burley
Journal:  J Struct Funct Genomics       Date:  2007-12-05

5.  Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.

Authors:  Klaus Hellmuth; Stefanie Grosskopf; Ching Tung Lum; Martin Würtele; Nadine Röder; Jens Peter von Kries; Marta Rosario; Jörg Rademann; Walter Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-14       Impact factor: 11.205

Review 6.  Small molecule tools for functional interrogation of protein tyrosine phosphatases.

Authors:  Rongjun He; Li-Fan Zeng; Yantao He; Sheng Zhang; Zhong-Yin Zhang
Journal:  FEBS J       Date:  2012-08-16       Impact factor: 5.542

7.  Investigating mammalian tyrosine phosphatase inhibitors as potential 'piggyback' leads to target Trypanosoma brucei transmission.

Authors:  Irene Ruberto; Balazs Szoor; Rachel Clark; Keith R Matthews
Journal:  Chem Biol Drug Des       Date:  2013-02       Impact factor: 2.817

8.  Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B.

Authors:  Thomas Scior; José Antonio Guevara-García; F J Melendez; Hassan H Abdallah; Quoc-Tuan Do; Philippe Bernard
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

9.  A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.

Authors:  Sheng Zhang; Sijiu Liu; Rongya Tao; Dan Wei; Lan Chen; Weihua Shen; Zhi-Hong Yu; Lina Wang; David R Jones; Xiaocheng C Dong; Zhong-Yin Zhang
Journal:  J Am Chem Soc       Date:  2012-10-17       Impact factor: 15.419

10.  Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.

Authors:  Thomas Scior; Hans-Georg Mack; José Antonio Guevara García; Wolfhard Koch
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.